MedTech News & Analysis
8 articles
Market Mood
J&J (JNJ) Reports Earnings Beat, Plans 2027 Spinoff
Johnson & Johnson (JNJ) reported earnings that surpassed analyst expectations, driven by strong sales of its immune disease drug, Tremfya. The company also announced plans to spin off its hips-and-knees business, DePuy Synthes, into a standalone company by mid-2027. J&J sees a spin as creating long-term value for shareholders. Apollo Global Management is currently in talks to acquire the unit for an estimated $20 billion, according to Bloomberg. Revenue from J&J's medical technology division rose 2.5% to $8.6 billion, falling short of the $8.71 billion analysts anticipated. International sales remained flat, affected by factors including the Middle East conflict, European austerity measures, and pricing challenges in China. Despite external pressures, the company increased its full-year sales forecast to about $101.2 billion and adjusted its earnings forecast to a midpoint of $11.10 per share. The spin-off of DePuy Synthes reflects J&J's strategy to focus on higher-growth sectors within healthcare. This separation is likely to allow both companies to allocate resources more effectively, aiming for enhanced performance in their respective markets. For investors, the planned spin-off and raised forecasts indicate J&J's commitment to sustained growth.
Read More: J&J (JNJ) Reports Earnings Beat, Plans 2027 Spinoff
Boston Scientific (BSX) Guidance Cut Due to Cyberattack Impact
Boston Scientific Corporation (NYSE: BSX) experienced a 2.3% decline in trading on September 8, 2026, following a cyberattack on August 25 that disrupted manufacturing and shipping. The company announced it is unlikely to meet its previously provided guidance for third-quarter and full-year net sales and adjusted earnings per share for 2026. While operations have resumed, the cyberattack’s effects are anticipated to impact the company's financial performance. This situation highlights operational vulnerabilities that investors might not have fully considered, creating caution regarding future earnings expectations.
Read More: Boston Scientific (BSX) Guidance Cut Due to Cyberattack Impact
MedTech Solutions Outlines 2025-2027 Development Strategy Plan
MedTech Solutions has refined its development strategy for the years 2025 to 2027. The company aims to enhance its operations and expand its market presence during this period. No specific financial figures or metrics were disclosed in relation to this strategy update. Investors will want to monitor how this new direction may affect future growth opportunities and overall market positioning for MedTech Solutions.
Read More: MedTech Solutions Outlines 2025-2027 Development Strategy Plan
Medtronic (MDT) Reports 9.9% Q4 Revenue Growth, UBS Upgrades Stock
Medtronic (NYSE: MDT) announced Q4 revenue of $9.8 billion, reflecting a 9.9% increase, while fiscal 2026 revenue reached $36.4 billion, up 8.4%. The company achieved its highest annual revenue growth in 10 years, driven by significant performance in its cardiac segment, with Cardiac Ablation Solutions revenue increasing by 78%. UBS upgraded Medtronic from Neutral to Buy, citing signs of a turnaround after several years of underperformance. This information is important for investors as it indicates potential renewed growth and improved prospects for Medtronic, factoring into decisions on stock valuation and investment strategies.
Read More: Medtronic (MDT) Reports 9.9% Q4 Revenue Growth, UBS Upgrades Stock
CeriBell, Inc. (CBLL) Study Links Seizure Burden with Disability
CeriBell, Inc. (CBLL) reported findings from a study involving 359 adult patients published in Critical Care Medicine. The study indicates that a peak seizure burden of at least 90% correlates with a 3.4 times higher likelihood of death or severe disability at discharge. Additionally, every hour of AI-detected seizure activity nearly doubles the odds of severe outcomes, with an adjusted odds ratio of 1.98. These findings highlight the importance of continuous monitoring for improved clinical decisions and potential earlier interventions for patients with severe neurological conditions.
Read More: CeriBell, Inc. (CBLL) Study Links Seizure Burden with Disability
Medtronic (MDT) Gains FDA Approval for New Robotic Surgery Platform
Medtronic (MDT) received FDA approval for its Hugo robotic-assisted surgery platform in December 2025, allowing it to perform urologic procedures. The first successful use occurred at Cleveland Clinic shortly after. This market is projected to grow from $13.8 billion in 2022 to $63.7 billion by 2035, yet Medtronic faces significant competition from Intuitive Surgical, which dominates the market with over 11,395 da Vinci systems installed globally. With a recent application for broader procedure approvals, Medtronic aims to expand its market presence but may have an uphill battle against a well-entrenched competitor.
Read More: Medtronic (MDT) Gains FDA Approval for New Robotic Surgery Platform
Becton Dickinson (BDX) Price Target Trimmed to $159 by Piper Sandler
Piper Sandler has reduced the price target for Becton, Dickinson and Company (BDX) from $170 to $159 while maintaining a Neutral rating. This adjustment was made on April 17, 2026, to align with management's revenue growth guidance. Additionally, RBC Capital Markets lowered its price target for BDX to $175 from $195, citing stable fundamentals in the MedTech sector. Both firms note that current sentiment around BDX may create investment opportunities, but they expect the stock to remain range-bound due to a lack of clear catalysts.
Read More: Becton Dickinson (BDX) Price Target Trimmed to $159 by Piper Sandler
Medtech Industry Growth Driven by Infrastructure Investments Over Next Decade
The medtech sector is expected to see significant growth over the next decade, largely fueled by increased investments in healthcare infrastructure. This shift is crucial as it aligns with trends towards more advanced and accessible medical technologies, reflecting a broader commitment to enhancing patient care. Key data indicates that the industry could witness a compound annual growth rate (CAGR) exceeding 5% during this period. Market analysts suggest that these foundational developments will not only bolster medtech stocks but also trigger a ripple effect throughout related sectors.
Read More: Medtech Industry Growth Driven by Infrastructure Investments Over Next Decade